FLT3-ITD mutations do not impact the outcome of patients allografted with partial T-cell depleted grafts for AML with normal cytogenetics in first complete remission

Hematol Oncol. 2017 Sep;35(3):392-394. doi: 10.1002/hon.2272. Epub 2015 Nov 13.

Authors

Yan Beauverd¹, Olga Tsopra¹, Eddy Roosnek¹, Audrey Simon¹, Anne-Pascale Grandjean¹, Yordanka Tirefort¹, Carole Dantin¹, Stavroula Masouridi-Levrat¹, Yves Chalandon¹

Affiliation

¹ Stem Cell and Bone Marrow Transplant Centre, Division of Hematology, Geneva's University Hospitals and University of Geneva Faculty of Medicine, 4 Rue Gabrielle Perret-Gentil, 1205, Geneva, Switzerland.

PMID: 26563907
DOI: 10.1002/hon.2272

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Allografts
Disease-Free Survival
Female
Graft Enhancement, Immunologic*
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / mortality
Leukemia, Myeloid, Acute* / therapy
Lymphocyte Depletion*
Male
Middle Aged
Mutation*
Retrospective Studies
Survival Rate
fms-Like Tyrosine Kinase 3 / genetics*

Substances

FLT3 protein, human
fms-Like Tyrosine Kinase 3